Mesenchymal stem cell therapy for Crohn's perianal fistula—a real‐world experience
Colorectal Disease · 2024
DOI: 10.1111/codi.16830 ↗Kurz gefasst
Fachartikel in der Zeitschrift Colorectal Disease, 2024. Verfasst von Ian White und 7 weiteren Autor:innen. Beteiligte Einrichtung: Colorectal Unit, Division of Surgery, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel. Hauptthemen laut MEDLINE: Crohn Disease, Mesenchymal Stem Cell Transplantation, Rectal Fistula, Mesenchymal Stem Cells. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aim
Remission rates of medically and surgically treated complex perianal fistulas in Crohn's disease are low. Recently, trials have demonstrated the potential for long‐term remission with local injection of allogeneic adipose‐derived mesenchymal stem cells (darvadstrocel). Our aim was to analyse outcomes from our real‐world experience with this new treatment.
Methods
All patients with Crohn's disease suffering complex perianal fistulas who consecutively underwent administration of darvadstrocel at two centres were followed up and evaluated. Patients were assessed for clinical remission, response, failure, and any complications during follow‐up. The results of all patients with a minimum of 3 months’ follow‐up are presented.
Results
Thirty‐three patients with Crohn's disease and complex perianal fistulas were included. Of these, 20 (61%) experienced clinical remission that was maintained for a mean follow‐up of 14 (3–32) months. A total of 24 of 33 (73%) experienced at least 3 months of clinical remission, with four later having recurrence (3–12 months). Among the remaining nine patients who did not experience clinical remission, two (6%) had partial remission (such as one of two fistulas closing), two (6%) showed signs of response but not remission, and five (15%) showed no signs of healing. The mean time to maintained clinical remission was 6 weeks (range 2 weeks to 6 months), and there were no severe adverse events.
Conclusion
In this real‐world experience, treatment of Crohn's disease complex perianal fistulas with darvadstrocel had a 61% success rate for maintained clinical remission.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Colorectal Unit, Division of Surgery, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel.
- Surgery B Department, Meir Medical Center, Kfar Saba, Israel.
- Gastroenterology Department, Meir Medical Center, Kfar Saba, Israel.
ORCID-Profile: Ian White
Zitieren
APA
White, I., Yanai, H., Avni, I., Slavin, M., Naftali, T., Tovi, S., Dotan, I., & Wasserberg, N. (2024). Mesenchymal stem cell therapy for Crohn's perianal fistula—a real‐world experience. Colorectal Disease. https://doi.org/10.1111/codi.16830
Vancouver
White I, Yanai H, Avni I, Slavin M, Naftali T, Tovi S, et al. Mesenchymal stem cell therapy for Crohn's perianal fistula—a real‐world experience. Colorectal Disease. 2024. doi:10.1111/codi.16830
BibTeX
@article{White2024,
author = {White, Ian and Yanai, Henit and Avni, Irit and Slavin, Moran and Naftali, Timna and Tovi, Shifra and Dotan, Iris and Wasserberg, Nir},
title = {Mesenchymal stem cell therapy for Crohn's perianal fistula—a real‐world experience},
journal = {Colorectal Disease},
year = {2024},
doi = {10.1111/codi.16830}
}
EUVIMED